Renaissance Technologies LLC Purchases 40,800 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Renaissance Technologies LLC lifted its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 67.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 101,248 shares of the company's stock after acquiring an additional 40,800 shares during the period. Renaissance Technologies LLC owned approximately 0.21% of Mirum Pharmaceuticals worth $4,187,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Jones Financial Companies Lllp lifted its stake in shares of Mirum Pharmaceuticals by 100.0% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock valued at $30,000 after buying an additional 357 shares during the period. R Squared Ltd bought a new stake in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $69,000. AlphaQuest LLC grew its holdings in shares of Mirum Pharmaceuticals by 969.6% during the 4th quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock worth $76,000 after purchasing an additional 1,658 shares in the last quarter. Avanza Fonder AB bought a new stake in shares of Mirum Pharmaceuticals during the fourth quarter valued at approximately $189,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in Mirum Pharmaceuticals during the fourth quarter worth $277,000.

Insiders Place Their Bets

In other news, SVP Jolanda Howe sold 1,064 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $48.22, for a total transaction of $51,306.08. Following the completion of the sale, the senior vice president now owns 4,232 shares in the company, valued at $204,067.04. The trade was a 20.09 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Christopher Peetz sold 9,102 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total transaction of $438,898.44. Following the sale, the chief executive officer now directly owns 115,920 shares of the company's stock, valued at approximately $5,589,662.40. This trade represents a 7.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 105,557 shares of company stock valued at $4,726,040. 22.87% of the stock is currently owned by corporate insiders.

Mirum Pharmaceuticals Price Performance

Shares of MIRM stock traded up $0.33 during trading hours on Friday, hitting $40.80. 186,097 shares of the company's stock were exchanged, compared to its average volume of 521,493. The stock's 50-day moving average is $44.12 and its 200-day moving average is $43.97. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.83 and a 52 week high of $54.23. The stock has a market cap of $2.02 billion, a price-to-earnings ratio of -20.20 and a beta of 1.00.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company had revenue of $99.41 million during the quarter, compared to analyst estimates of $96.64 million. As a group, research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on MIRM shares. HC Wainwright increased their price target on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Robert W. Baird raised their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a research report on Thursday, February 27th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $58.20.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.